Related Experiment Video
Updated: Aug 21, 2025
Author Spotlight: Exploring Strategies for Successful Immune Response Against Tumors
Published on: August 16, 2024
Nanotheranostic Strategies for Cancer Immunotherapy
Anh Nguyen1, Sahana Kumar1, Ashish A Kulkarni1,2
1Department of Chemical Engineering, University of Massachusetts, Amherst, MA, 01003, USA.
Abstract:
Despite advancements in cancer immunotherapy, heterogeneity in tumor response impose barriers to successful treatments and accurate prognosis. Effective therapy and early outcome detection are critical as toxicity profiles following immunotherapies can severely affect patients' quality of life. Existing imaging techniques, including positron emission tomography, computed tomography, magnetic resonance imaging, or multiplexed imaging, are often used in clinics yet suffer from limitations in the early assessment of immune response. Conventional strategies to validate immune response mainly rely on the Response Evaluation Criteria in Solid Tumors (RECIST) and the modified iRECIST for immuno-oncology drug trials. However, accurate monitoring of immunotherapy efficacy is challenging since the response does not always follow conventional RECIST criteria due to delayed and variable kinetics in immunotherapy responses. Engineered nanomaterials for immunotherapy applications have significantly contributed to overcoming these challenges by improving drug delivery and dynamic imaging techniques. This review summarizes challenges in recent immune-modulation approaches and traditional imaging tools, followed by emerging developments in three-in-one nanoimmunotheranostic systems co-opting nanotechnology, immunotherapy, and imaging. In addition, a comprehensive overview of imaging modalities in recent cancer immunotherapy research and a brief outlook on how nanotheranostic platforms can potentially advance to clinical translations for the field of immuno-oncology is presented.
Insights
Cancer immunotherapy faces challenges with varied patient responses and limited early detection. Novel nanoimmunotheranostic systems integrate nanotechnology, immunotherapy, and imaging for improved treatment monitoring and outcomes.
Area of Science:
- Oncology
- Nanotechnology
- Medical Imaging
Background:
- Cancer immunotherapy shows promise but faces challenges due to heterogeneous tumor responses and limitations in current imaging techniques for early assessment.
- Traditional methods like RECIST (Response Evaluation Criteria in Solid Tumors) struggle to accurately monitor immunotherapy efficacy due to delayed and variable response kinetics.
- Toxicity from immunotherapies necessitates effective early outcome detection to improve patient quality of life.
Purpose of the Study:
- To review challenges in current cancer immunotherapy and imaging approaches.
- To explore emerging three-in-one nanoimmunotheranostic systems that combine nanotechnology, immunotherapy, and imaging.
- To provide an overview of imaging modalities in cancer immunotherapy research and discuss the clinical translation potential of nanotheranostic platforms.
Main Methods:
- Literature review of recent advancements in immune-modulation, traditional imaging tools, and engineered nanomaterials for immunotherapy.
- Analysis of emerging nanoimmunotheranostic systems integrating nanotechnology, immunotherapy, and imaging.
- Comprehensive overview of imaging modalities used in cancer immunotherapy research.
Main Results:
- Engineered nanomaterials offer improved drug delivery and dynamic imaging capabilities for immunotherapy.
- Three-in-one nanoimmunotheranostic systems represent a promising development for overcoming limitations in current approaches.
- Nanotheranostic platforms hold potential for advancing clinical translation in immuno-oncology.
Conclusions:
- Nanoimmunotheranostic systems offer a novel approach to address challenges in cancer immunotherapy monitoring and treatment.
- Integrating nanotechnology, immunotherapy, and imaging can lead to more effective and personalized cancer treatments.
- Further development and clinical translation of nanotheranostic platforms are crucial for the future of immuno-oncology.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...